Iambic Therapeutics IPO: revenue, losses and offering terms from its S-1
Iambic Therapeutics priced its IPO at $16 a share on 15 Oct 2026 and raised $150 million. Its shares trade on Nasdaq as IAM. Revenue was $9.4 million in 2025, up 7.9 times from 2024, with a net loss of $77.3 million.
Headlines
- Revenue, 2025
- $9M
- Up 7.9 times on the year before
- Net loss, 2025
- $77M
- Revenue, First half of 2026
- $13M
- Up 3.2 times on a year earlier
- IPO price
- $16
- $150M raised
Iambic Therapeutics IPO terms
From the final prospectus (424B4).
- Exchange
- Nasdaq Global Select Market
- Ticker
- IAM
- IPO price
- $16
- Shares offered
- 9,375,000
- Raised
- $150M
- Registered
- $183M, the amount the filing fee is paid on
- Underwriters
- J.P. Morgan, Jefferies, BofA Securities and Citigroup
- First filed
- 21 Sep 2026
Iambic Therapeutics revenue and profit
| Period | Revenue | Operating income | Net income |
|---|---|---|---|
| 2024 | $1M | - | -$48M |
| 2025 | $9M | -$82M | -$77M |
| First half of 2025 | $4M | - | - |
| First half of 2026 | $13M | -$54M | -$50M |
Iambic Therapeutics share structure and company facts
- Employees
- 171
- Headquarters
- San Diego, California
Iambic Therapeutics shares since the IPO
Latest close 26 Oct 2026
- IPO price
- $16
- Priced 15 Oct 2026
- First close
- $18.91
- +18% on the IPO price
- Latest close
- $14.41
- -10% on the IPO price
Iambic Therapeutics' IPO filings
The registration statement, each amendment and the final prospectus, oldest first.
About the data
- Terms and financials are read from Iambic Therapeutics' newest prospectus (424B4 filed 15 Oct 2026) by a Kadoa workflow. Check figures that matter against the filing.
- Registered is the amount the filing fee is paid on, often a placeholder before the price range is set.
- Raised is the IPO price times the shares sold, without the underwriters' option. Trading compares the first and latest close with the IPO price.